NYSE:ECL 2 December 2025

May 30, 2026, 6:54 PM EDT. Nanobiotix (ENXTPA:NANO) completed a €85 million global equity raise to fund the development of JNJ-1900 (NBTXR3), a leading cancer treatment candidate. The financing follows promising Phase 2 trial results in inoperable non-small cell lung cancer, sponsored by Johnson & Johnson. Despite a recent 6.6% dip, shares have soared over 79% year-to-date, closing at €34.04, reflecting high market sensitivity to company developments. The fundraise attracted both European and U.S. investors through ordinary shares, American Depositary Shares, and pre-funded warrants issued near the current share price, suggesting robust demand without steep discounting. Investors will closely monitor Nanobiotix's clinical progress, regulatory updates, and potential partnerships, amid dilution concerns due to the new equity issue.